<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198883</url>
  </required_header>
  <id_info>
    <org_study_id>CellProthera</org_study_id>
    <nct_id>NCT04198883</nct_id>
  </id_info>
  <brief_title>SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)</brief_title>
  <acronym>SingXpand</acronym>
  <official_title>SINGaporean Program Performed With an eXPANsion Medical Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellProthera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellProthera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the pilot study is to evaluate the safety and the individual efficacy of the&#xD;
      use of ProtheraCytes® in patients with acute myocardial infarction and decreased ejection&#xD;
      fraction. CD34+ cells will be re-injected using a dedicated catheter pushed through the&#xD;
      femoral artery up to the left ventricle, thus avoiding open chest surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective : The objective is to establish the safety of the interventional procedure&#xD;
      beginning at the first G-CSF administration to 6 months after the injection of autologous&#xD;
      expanded CD34+ stem cells (ProtheraCytes®) in AMI patients with a LVEF≤45% after PTCA and&#xD;
      stent(s) implantation.&#xD;
&#xD;
      Secondary Objective : The objective is to establish the individual efficacy of the&#xD;
      interventional procedure beginning at the first G-CSF administration to 6 months after the&#xD;
      injection of autologous expanded CD34+ stem cells (ProtheraCytes®) in AMI patients with a&#xD;
      LVEF≤45% after PTCA and stent(s) implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>the design : pilot, single-arm, open-labelled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE,SAE and AE</measure>
    <time_frame>1 year</time_frame>
    <description>Description, incidence and assessment of MACE (Major Adverse Cardiac Events), SAE and AE .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Cardiac function assessed by cMRI</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of individual change of cardiac function via cardiac MRI performed at screening, and 3, 6 &amp; 12 months after ProtheraCytes® administration.&#xD;
Assessment of Cardiac Event Free Survival.&#xD;
Median Time assessment between treatment procedure onset and cardiac relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Attack</condition>
  <arm_group>
    <arm_group_label>Protheracytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study : Stem cells injection called Protheracytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Protheracytes</intervention_name>
    <description>Intramyocardiac (LV) injection of stem cells with a dedicated catheter</description>
    <arm_group_label>Protheracytes</arm_group_label>
    <other_name>Biocardia Helix catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. De Novo AMI with or without ST segment elevation and with a detection of rise and/or&#xD;
             fall of cardiac biomarker values (troponin) with at least one value above the 99th&#xD;
             percentile of the upper reference limit.&#xD;
&#xD;
          2. Anterior wall AMI&#xD;
&#xD;
          3. PTCA and stent(s) implantation (=Day 0)&#xD;
&#xD;
          4. LVEF ≤ 45% after stent(s) implantation: Combination of a LVEF ≤ 45 % and of anterior&#xD;
             akinetic segment(s) - by echography at Day 2 ± 1 after stent(s) implantations&#xD;
&#xD;
          5. Age must be ≥ 21 and ≤ 80 years&#xD;
&#xD;
          6. Men and Non-pregnant non-lactating women who take efficacious contraceptive measures&#xD;
             such as oral contraceptive medications or efficacious and permanent intra-uterine&#xD;
             device (drug eluted or not) (IUD) or subcutaneous permanent contraceptive implants or&#xD;
             menopaused women (at least a 2 years confirmed menopause) or surgically sterilized&#xD;
             women.&#xD;
&#xD;
          7. Having previously signed a written informed consent prior to any study-specific&#xD;
             procedures.&#xD;
&#xD;
          8. LVEF remaining ≤ 45% assessed by a 2nd echography at Day 8 (± 2) after stent(s)&#xD;
             implantation.&#xD;
&#xD;
             If these criteria have been validated, then the following assessments will be carried&#xD;
             out only after the 2nd echography&#xD;
&#xD;
          9. LVEF remaining ≤ 45% assessed by cMRI&#xD;
&#xD;
         10. Identification of anterior akinetic segment(s) of interest assessed by cMRI&#xD;
&#xD;
         11. Identification of non-viability of anterior segment(s) of interest assessed by cMRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous and known symptomatic CHF, from class II to IV (included)&#xD;
&#xD;
          2. History of CABG (Coronary Artery Bypass Surgery) surgery&#xD;
&#xD;
          3. History of former significant mitral valve replacement surgery or heart&#xD;
             transplantation.&#xD;
&#xD;
          4. Severe valve disease: mitral, aortic stenosis / insufficiency.&#xD;
&#xD;
          5. Diagnosis of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral&#xD;
             regurgitation, tachycardia, or myocarditis&#xD;
&#xD;
          6. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter&#xD;
             access to LV&#xD;
&#xD;
          7. Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive&#xD;
             device.&#xD;
&#xD;
          8. Documented presence of a known LV thrombus&#xD;
&#xD;
          9. Sepsis&#xD;
&#xD;
         10. Endocarditis&#xD;
&#xD;
         11. Infectious pericarditis&#xD;
&#xD;
         12. Pericardial tamponade&#xD;
&#xD;
         13. Left ventricular aneurysm, collagen tissue disease&#xD;
&#xD;
         14. Severe peripheral vascular disease precluding femoral artery access as determined at&#xD;
             the time of original catheterization.&#xD;
&#xD;
         15. Pacemaker, implantable cardiac defibrillator, and intra-cerebral aneurysm clips.&#xD;
&#xD;
         16. History of metallic foreign body in their eye&#xD;
&#xD;
         17. Former or current aortic dissection&#xD;
&#xD;
         18. Inadequate bone marrow function: Haemoglobin &lt; 10 g/dL and Platelet count &lt; 100 x 109&#xD;
             / L&#xD;
&#xD;
         19. Previous G-CSF or other Hematopoietic Growth Factor administrations.&#xD;
&#xD;
         20. Blood transfusion(s) within the previous 4 weeks (to exclude potential non-autologous&#xD;
             ACPs (Angiogenic Cells Precursors) in the harvested blood).&#xD;
&#xD;
         21. Hepatic failure or history of liver cirrhosis or hepatic severe impairment.&#xD;
&#xD;
         22. Constitutional or acquired coagulopathy&#xD;
&#xD;
         23. Treated chronic renal failure, or haemodialysis or renal severe impairment (creatinine&#xD;
             clearance &lt; 30ml/min).&#xD;
&#xD;
         24. Prior or concomitant malignancies except non-melanoma skin cancer or adequately&#xD;
             treated in situ cervical cancer or previous cancer in complete response without any&#xD;
             treatment in the last 5 years.&#xD;
&#xD;
         25. History of prior mediastinal radiation exposure&#xD;
&#xD;
         26. Serious underlying medical conditions at the investigator's discretion, which could&#xD;
             impair the ability of the patient to participate in the trial (e.g. ongoing infection,&#xD;
             active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple&#xD;
             Sclerosis).&#xD;
&#xD;
         27. Chronic immunomodulatory or cytotoxic drug treatment intake.&#xD;
&#xD;
         28. Active bleeding or major surgery within 1 month.&#xD;
&#xD;
         29. Human immunodeficiency HIV1-2, HTLV1, HTLV2&#xD;
&#xD;
         30. History or current Hepatitis B (prior vaccination accepted)&#xD;
&#xD;
         31. History or current Hepatitis C&#xD;
&#xD;
         32. Syphilis&#xD;
&#xD;
         33. Chronic Obstructive Pulmonary Disease.&#xD;
&#xD;
         34. Active participation in any other clinical trials&#xD;
&#xD;
         35. Current or recent treatment (within the 60 days period before PTCA and stent(s)&#xD;
             implantation) with another investigational drug or procedure.&#xD;
&#xD;
         36. Any other co-existing conditions that will preclude participation in the study or&#xD;
             compromise ability to give informed consent.&#xD;
&#xD;
         37. Requirement of i.v. catecholamines or mechanical hemodynamic support (aortic balloon&#xD;
             pump) initiated 24 hours before cMRI.&#xD;
&#xD;
         38. Splenomegaly&#xD;
&#xD;
         39. Phenylketonuria&#xD;
&#xD;
         40. History of iron-Dextran allergy&#xD;
&#xD;
         41. History of murin protein allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Flandrin</last_name>
    <role>Study Director</role>
    <affiliation>CellProthera</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHCS</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

